208 related articles for article (PubMed ID: 23458841)
1. Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012).
Supuran CT; Carta F; Scozzafava A
Expert Opin Ther Pat; 2013 Jul; 23(7):777-88. PubMed ID: 23458841
[TBL] [Abstract][Full Text] [Related]
2. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Cuny GD
Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
[TBL] [Abstract][Full Text] [Related]
3. LpxC inhibitors: a patent review (2010-2016).
Kalinin DV; Holl R
Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
[TBL] [Abstract][Full Text] [Related]
4. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
5. Research and development of antibiotics: insights from patents and citation network.
Zhang M; Kong X; Zheng J; Wan JB; Wang Y; Hu Y; Shao R
Expert Opin Ther Pat; 2016 May; 26(5):617-27. PubMed ID: 26986226
[TBL] [Abstract][Full Text] [Related]
6. Anti-infective carbonic anhydrase inhibitors: a patent and literature review.
Capasso C; Supuran CT
Expert Opin Ther Pat; 2013; 23(6):693-704. PubMed ID: 23488877
[TBL] [Abstract][Full Text] [Related]
7. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
8. Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target.
Lee CR; Lee JH; Jeong BC; Lee SH
Curr Pharm Des; 2013; 19(36):6534-50. PubMed ID: 23829374
[TBL] [Abstract][Full Text] [Related]
9. What is in the pipeline for Gram-negative pathogens?
Talbot GH
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
[TBL] [Abstract][Full Text] [Related]
10. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
Briers Y; Lavigne R
Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461
[TBL] [Abstract][Full Text] [Related]
11. Will new antimicrobials overcome resistance among Gram-negatives?
Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
[TBL] [Abstract][Full Text] [Related]
12. Combating multidrug-resistant Gram-negative bacterial infections.
Xu ZQ; Flavin MT; Flavin J
Expert Opin Investig Drugs; 2014 Feb; 23(2):163-82. PubMed ID: 24215473
[TBL] [Abstract][Full Text] [Related]
13. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
14. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement.
Chopra I; Schofield C; Everett M; O'Neill A; Miller K; Wilcox M; Frère JM; Dawson M; Czaplewski L; Urleb U; Courvalin P
Lancet Infect Dis; 2008 Feb; 8(2):133-9. PubMed ID: 18222164
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections.
Suárez CJ; Lolans K; Villegas MV; Quinn JP
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):915-22. PubMed ID: 16307504
[TBL] [Abstract][Full Text] [Related]
16. Polymyxin derivatives: a patent evaluation (WO2012168820).
Wu H; Teng P; Niu Y; Li Q; Cai J
Expert Opin Ther Pat; 2013 Aug; 23(8):1075-81. PubMed ID: 23806121
[TBL] [Abstract][Full Text] [Related]
17. The development of efflux pump inhibitors to treat Gram-negative infections.
Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M
Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793
[TBL] [Abstract][Full Text] [Related]
18. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
Vergidis PI; Falagas ME
Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
[TBL] [Abstract][Full Text] [Related]
19. New aminoglycoside antibiotics.
Dozzo P; Moser HE
Expert Opin Ther Pat; 2010 Oct; 20(10):1321-41. PubMed ID: 20670208
[TBL] [Abstract][Full Text] [Related]
20. Bacterial resistance, beta-lactam antibiotics and gramnegative bacteria at ICUs.
Reisinger EC; Allerberger F
Wien Klin Wochenschr; 1999 Jul; 111(14):537-8. PubMed ID: 10467639
[No Abstract] [Full Text] [Related]
[Next] [New Search]
